These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 34083237)

  • 1. Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma.
    Kim SY; Kim SM; Lim S; Lee JY; Choi SJ; Yang SD; Yun MR; Kim CG; Gu SR; Park C; Park AY; Lim SM; Heo SG; Kim H; Cho BC
    Clin Cancer Res; 2021 Aug; 27(15):4397-4409. PubMed ID: 34083237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An In Vitro System for Evaluating Molecular Targeted Drugs Using Lung Patient-Derived Tumor Organoids.
    Takahashi N; Hoshi H; Higa A; Hiyama G; Tamura H; Ogawa M; Takagi K; Goda K; Okabe N; Muto S; Suzuki H; Shimomura K; Watanabe S; Takagi M
    Cells; 2019 May; 8(5):. PubMed ID: 31137590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations.
    Liang SK; Ko JC; Yang JC; Shih JY
    Lung Cancer; 2019 Jul; 133():103-109. PubMed ID: 31200815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
    Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
    Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients.
    Chen JH; Chu XP; Zhang JT; Nie Q; Tang WF; Su J; Yan HH; Zheng HP; Chen ZX; Chen X; Song MM; Yi X; Li PS; Guan YF; Li G; Deng CX; Rosell R; Wu YL; Zhong WZ
    Thorac Cancer; 2020 Aug; 11(8):2279-2290. PubMed ID: 32633046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
    Pamarthy S; Sabaawy HE
    Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse Event Management in Patients with
    Chalmers A; Cannon L; Akerley W
    Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine.
    Taverna JA; Hung CN; Williams M; Williams R; Chen M; Kamali S; Sambandam V; Hsiang-Ling Chiu C; Osmulski PA; Gaczynska ME; DeArmond DT; Gaspard C; Mancini M; Kusi M; Pandya AN; Song L; Jin L; Schiavini P; Chen CL
    Lung Cancer; 2024 Apr; 190():107533. PubMed ID: 38520909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived organoids as a platform for modeling a patient's response to chemoradiotherapy in esophageal cancer.
    Karakasheva TA; Gabre JT; Sachdeva UM; Cruz-Acuña R; Lin EW; DeMarshall M; Falk GW; Ginsberg GG; Yang Z; Kim MM; Diffenderfer ES; Pitarresi JR; Li J; Muir AB; Hamilton KE; Nakagawa H; Bass AJ; Rustgi AK
    Sci Rep; 2021 Oct; 11(1):21304. PubMed ID: 34716381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-derived organoids of non-small cells lung cancer and their application for drug screening.
    Li YF; Gao Y; Liang BW; Cao XQ; Sun ZJ; Yu JH; Liu ZD; Han Y
    Neoplasma; 2020 Mar; 67(2):430-437. PubMed ID: 31973535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung adenocarcinoma organoids harboring EGFR 19Del and L643V double mutations respond to osimertinib and gefitinib: A case report.
    Bie Y; Wang J; Xiong L; Wang D; Liao J; Zhang Y; Lin H
    Medicine (Baltimore); 2021 Mar; 100(11):e24793. PubMed ID: 33725945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer.
    Cartry J; Bedja S; Boilève A; Mathieu JRR; Gontran E; Annereau M; Job B; Mouawia A; Mathias P; De Baère T; Italiano A; Besse B; Sourrouille I; Gelli M; Bani MA; Dartigues P; Hollebecque A; Smolenschi C; Ducreux M; Malka D; Jaulin F
    J Exp Clin Cancer Res; 2023 Oct; 42(1):281. PubMed ID: 37880806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation.
    Li J; Zhu L; Stebbing J; Peng L
    J Cancer Res Ther; 2022 Sep; 18(5):1436-1439. PubMed ID: 36204894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).
    Aisner DL; Sholl LM; Berry LD; Rossi MR; Chen H; Fujimoto J; Moreira AL; Ramalingam SS; Villaruz LC; Otterson GA; Haura E; Politi K; Glisson B; Cetnar J; Garon EB; Schiller J; Waqar SN; Sequist LV; Brahmer J; Shyr Y; Kugler K; Wistuba II; Johnson BE; Minna JD; Kris MG; Bunn PA; Kwiatkowski DJ;
    Clin Cancer Res; 2018 Mar; 24(5):1038-1047. PubMed ID: 29217530
    [No Abstract]   [Full Text] [Related]  

  • 16. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer.
    Shi R; Radulovich N; Ng C; Liu N; Notsuda H; Cabanero M; Martins-Filho SN; Raghavan V; Li Q; Mer AS; Rosen JC; Li M; Wang YH; Tamblyn L; Pham NA; Haibe-Kains B; Liu G; Moghal N; Tsao MS
    Clin Cancer Res; 2020 Mar; 26(5):1162-1174. PubMed ID: 31694835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
    Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
    Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy generated by afatinib in a lung adenocarcinoma patient harboring HER2 S310Y mutation.
    Wang J; Wen Y; Ding G; Ding P; Zhang L; Liu J; Zhang T; Yang L
    Cancer Biol Ther; 2018 Jun; 19(6):450-453. PubMed ID: 29561699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing.
    Zu M; Hao X; Ning J; Zhou X; Gong Y; Lang Y; Xu W; Zhang J; Ding S
    Biomed Pharmacother; 2023 Jul; 163():114751. PubMed ID: 37105073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.